We serve Chemical Name:(R)-(5-Oxotetrahydrofuran-2-yl)methyl 4-methylbenzenesulfonate CAS:58879-33-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(R)-(5-Oxotetrahydrofuran-2-yl)methyl 4-methylbenzenesulfonate
CAS.NO:58879-33-7
Synonyms:MFCD00274611;[(2R)-5-oxooxolan-2-yl]methyl 4-methylbenzenesulfonate
Molecular Formula:C12H14O5S
Molecular Weight:270.30200
HS Code:2932190090
Physical and Chemical Properties:
Melting point:85-88ºC
Boiling point:476.5ºC at 760 mmHg
Density:1.311g/cm3
Index of Refraction:1.542
PSA:78.05000
Exact Mass:270.05600
LogP:2.48670
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like MFCD00274611 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,[(2R)-5-oxooxolan-2-yl]methyl 4-methylbenzenesulfonate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00274611 Use and application,MFCD00274611 technical grade,usp/ep/jp grade.
Related News: SARS-CoV-2 has evolved mutations that severely compromise the neutralizing activities of multiple IgG monoclonal antibodies, including those under clinical trials and authorized for emergency use.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. opt.-inakt. 2,4-Dibrom-cyclobutanon-(1) manufacturers The company was one of many to step into the void for needed generic medicines as chronic shortages crippled access to key drugs, specifically in the early- to mid-stages of the pandemic. That shortage actually led the FDA to thaw its relationship with compounding pharmacies — which was once particularly icy — to ramp up production. 1-Hexadecanol, 2-(hexylamino)- suppliers Here’s how Biogen did during the three months ended June 30 compared with what Wall Street expected, according to average estimates compiled by Refinitiv. (3-((4-(((R)-2,2-dimethyl-1-(5-methylfuran-2-yl)propyl)amino)-1-oxido-1,2,5-thiadiazol-3-yl)amino)-2-hydroxyphenyl)(morpholino)methanone vendor & factory.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. opt.-inakt. 2,4-Dibrom-cyclobutanon-(1) manufacturers The company was one of many to step into the void for needed generic medicines as chronic shortages crippled access to key drugs, specifically in the early- to mid-stages of the pandemic. That shortage actually led the FDA to thaw its relationship with compounding pharmacies — which was once particularly icy — to ramp up production. 1-Hexadecanol, 2-(hexylamino)- suppliers Here’s how Biogen did during the three months ended June 30 compared with what Wall Street expected, according to average estimates compiled by Refinitiv. (3-((4-(((R)-2,2-dimethyl-1-(5-methylfuran-2-yl)propyl)amino)-1-oxido-1,2,5-thiadiazol-3-yl)amino)-2-hydroxyphenyl)(morpholino)methanone vendor & factory.
